HIMS: Whale Dumps $26 MILLION on Telehealth Giants Next Move!

📅 September 15, 2025 | 🔥 Extreme Unusual Activity Detected

---

🎯 The Quick Take

Someone just SOLD $2.6 MILLION worth of HIMS call options heading into the March 2026 expiration! 🐋 This isn't just any trade - this scored an 8.5/10 EXTREME unusual score, a move that's 1,846x larger than average! With HIMS up 115% YTD and trading at $54.21, this massive bearish bet suggests someone with deep pockets thinks the telehealth rocket might be running out of fuel! 💊

---

🏢 Company Overview

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. With a market cap of $12.5 billion, this healthcare disruptor operates in the Services-Offices & Clinics of Doctors of Medicine sector, revolutionizing how Americans access everything from erectile dysfunction treatments to weight loss medications - all from their phones!

---

💰 The Option Flow Breakdown

📊 What Just Happened

Check out this monster trade that hit the tape at 9:59 AM:

Time	Symbol	Side	Type	Strike	Expiration	Premium	Volume	OI	Size	Spot Price	Option Price
09:59:36	HIMS	SELL	CALL	$80	2026-03-20	$2.6M	3.2K	428	3,200	$56.40	$8.12

🤓 What This Actually Means

Real talk: This trade scored an 8.5/10 EXTREME unusual score - that's "happens maybe once a year" territory! 🌋

Here's the translation for us regular folks:

The Call Sell (Bearish/Neutral Signal): - Collecting $8.12 per contract in premium - Giving up upside above $80 - Strike is 41.8% out-of-the-money - ~6 months until expiration (March 2026)

Strategy Analysis: - Covered Call Theory: Most likely a fund that owns HIMS shares selling calls to generate income - Max Profit: $2.6M if HIMS stays below $80 by March 2026 - Risk: Missing out on gains if HIMS rockets past $80 - Unusualness: 1,846x larger than average HIMS option trade!

Translation: This massive seller is either: 1. Taking profits on a bullish position (bearish signal) 2. A long-term holder generating income (neutral signal) 3. Betting HIMS won't reach $80 by March (bearish signal)

Either way, they're saying "I don't think HIMS is going to the moon anytime soon!" 🌙

---

📈 Technical Setup / Chart Check-Up

Looking at the YTD performance, HIMS has been on an absolute tear:

Key Metrics: - 🚀 YTD Return: +115.12% (!!!) - 📊 Current Price: $54.21 - 📈 Start of Year: $25.20 - 🔴 Max Drawdown: -63.34% (early year volatility) - 💪 Volatility: 11.70%

Technical Levels: - 🎯 Current: $54.21 - 🚀 Strike Target: $80 (47.5% upside needed!) - 📉 Recent Action: Stock at $56.40 when trade hit - 💚 YTD High Territory: Consolidating near highs

Translation: HIMS has already more than doubled this year! This whale is betting the easy money has been made! 💸

---

🎪 Catalysts

📆 Upcoming Events

💊 Testosterone Therapy Launch - 2026 - Exclusive KYZATREX® oral testosterone partnership with Marius Pharmaceuticals - Injectable testosterone options planned - Targeting 20 million U.S. men with low testosterone

🌍 International Expansion - 2026 - ZAVA acquisition brings 1.3M customers in UK, Germany, France - Canada launch planned with generic semaglutide - Multi-billion dollar market opportunity

📊 Q3 Earnings - November 3, 2025 - Q2 showed 72.6% YoY revenue growth - 2.4 million subscribers (30.8% growth) - Full year guidance: $2.3-2.4B revenue

🗓️ Past Events (Already Happened)

⚠️ FDA Warning Letter - September 12, 2025 - FDA issued warning about GLP-1 marketing practices - Concerns about compounded weight loss drug safety - Stock has held up despite regulatory pressure

🏋️ Weight Loss Business Update - Q2 2025 - Expected to generate $725M in 2025 - Offering compounded GLP-1s at lower costs than Ozempic/Wegovy - Facing potential legal challenges from Novo Nordisk

---

🎲 Price Targets & Probabilities

Based on the massive bearish option flow and upcoming catalysts:

🚀 Bull Case (25% chance)

Target: $65-70 by year-end - International expansion exceeds expectations - Testosterone launch drives new subscriber growth - Q3 earnings beat significantly - This whale gets burned on their call sale!

⚖️ Base Case (50% chance)

Target: $50-60 - Steady growth continues but at slower pace - FDA concerns create headwinds - Competition in GLP-1 space intensifies - Stock consolidates gains

😰 Bear Case (25% chance)

Target: $40-48 - FDA crackdown on compounded drugs - Margin compression continues - Growth deceleration spooks investors - This whale's bearish bet pays off!

---

💡 Trading Ideas

🛡️ Conservative Play: "Premium Collector Like the Whale"

• Strategy: Sell $60 covered calls, 30-45 days out
• Premium: ~$1.50-2.00 per contract
• Why it works: Generate income if you own shares, limited downside
• Risk: Missing upside if HIMS rallies hard

⚖️ Balanced Play: "Range Trader"

• Strategy: Iron condor $48/$52/$58/$62 for November
• Credit: ~$1.20 per spread
• Max profit: $120 per spread if HIMS stays between $52-58
• Why it works: Profit from consolidation after big YTD move

🚀 Aggressive Play: "Contrarian Bull"

• Strategy: Buy $60 calls for January 2026
• Cost: ~$3-4 per contract
• Why it works: Bet against the whale if you're bullish on catalysts
• Risk: Total loss if HIMS doesn't break $63-64

---

⚠️ Risk Factors

Let's keep it real - here's what could go wrong:

• Regulatory Hurricane: FDA scrutiny intensifying on compounded GLP-1s
• Valuation Stretched: Up 115% YTD - lots of good news priced in!
• Competition Heating Up: Big pharma fighting back on weight loss drugs
• Customer Acquisition Costs: Rising from $500 to over $1,500 per customer
• Margin Pressure: Gross margins down 491 basis points in Q2

---

🎯 The Bottom Line

Real talk: Someone just made a MASSIVE $2.6 million bearish bet on HIMS - a trade that's 1,846x larger than average! This isn't your average options trade, it's EXTREME! 🌋

Here's your action plan:

If you own HIMS: - Consider taking some profits after the 115% run - Watch the $60 resistance level closely - Maybe follow the whale and sell some covered calls?

If you're watching: - Wait for a pullback toward $48-50 - Q3 earnings on November 3rd is the next major catalyst - FDA regulatory clarity could provide entry opportunity

If you're bullish: - You're fighting a $2.6 million call seller - International expansion and testosterone launch are your catalysts - Consider waiting for better entry after consolidation

Mark your calendar: November 3rd (Q3 earnings) and March 20, 2026 (option expiration) are the key dates to watch! 🎢

Remember: When someone sells $2.6 million in calls on a stock that's already up 115%, they're either taking profits at the perfect time, or they're about to watch HIMS rocket past $80 and kick themselves. Given the FDA headwinds and stretched valuation, this whale might be onto something! 💰

---

⚠️ Options involve risk and are not suitable for all investors. This whale-sized bet is extraordinary and happens maybe once a year. Always do your own research and never invest more than you can afford to lose. Not financial advice - just one trader sharing what the big money is doing!